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Summary
This introductory type of article provides a brief overview of the current clinical status of 
sporadic colorectal cancer (CRC). CRC ranks as one of the most prevalent and incident cancers 
and is also between the deadliest ones worldwide, along with lung and breast cancers. A majori-
ty of CRCs are sporadic, with age being the most important risk factor. CRC appears to be a com-
plex, heterogeneous disease that involves multiple signaling pathways and tumors that appear 
histologically identical may have different prognoses and different responses to treatment. CRC 
develops through gradual accumulation of genetic and epigenetic changes, resulting in the tran-
sformation of normal colonic mucosa into invasive cancer. Basically, the treatment for colorectal 
cancer varies by tumor location, stage at diagnosis and patient’s general condition. Any available 
data about the genes and/or molecular pathways that regulate activities such as cell growth, de-
ath or apoptosis, DNA repair, malignant alteration, etc. should also be taken into consideration. 
Recent polychemotherapy protocols along with the use of inhibitors of the vascular endothelial 
growth factor (VEGF) and the epidermal growth factor receptor (EGFR) pathways have enhanced 
the therapeutic responses and potentially also the patient prognoses. The treatment of CRC is 
expected to become more and more routinely based on identified molecular CRC subtypes and 
on validated prognostic and predictive biomarkers relatively soon (within several years), which 
should provide to patients better therapeutic outcomes with less side-effects.
Keywords: colorectal cancer; biomarkers; chemotherapy; targeted therapy; radiotherapy; 
personalized medicine.
Colorectal cancer (CRC) ranks as one of the most common cancer types dia-
gnosed worldwide and also as one of leading causes of cancer death [1-3]. Clinical 
experience, supported by various pathohistological, chromosomal, and molecular 
biology data and analysis, indicate that CRC is a heterogeneous disease, so patients 
with clinicopathologically similar tumors and with the same disease stage might 
differ strikingly in terms of treatment response and survival, respectively [4-9].
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The aim of this short overview is to recapitulate the data which indicate that 
CRC is a heterogeneous group of tumors and to present the topics presented by the 
lecturers and discussed at this meeting. The topics were the following:  CRC inci-
dence, importance of optimal nutrition, molecular pathogenesis, novel diagnostic 
procedures and algorithms, pathohistological recommendations and algorithms, 
surgical approaches, systemic therapy, radiation therapy, drug pharmacogenomics 
and patient pharmacogenetics, therapy side-effects, and the importance of a multi-
disciplinary team in making therapeutic decisions and in taking care of patients.
Our understanding of colorectal cancer as a disease is in fact continuously evol-
ving. There are a number of known genes controlling growth factor pathways that 
may drive the development and progression of colorectal cancer. The risk of occu-
rrence and occurrence of colorectal cancer depends on the genetic characteristics 
of the individual (heritage and epigenetic changes), their diet, intestinal flora, and 
lifestyle. Colorectal cancer is hereditary in less than 5% of patients. In most patients 
with colorectal cancer (approximately 95%), the impact of heritage is not so high, so 
we refer to it as sporadic colorectal cancer. The lifestyle and nutritional recommen-
dations, particularly for sporadic CRC prevention, include increasing dietary fiber 
intake, reducing red and processed meat consumption and alcoholic drinks, as well 
as regular physical exercise [8-11].
Two to three major genetic pathways are implicated in colorectal cancer. Most of 
sporadic CRC (at least two thirds) derive from malignant altered adenoma. In additi-
on to genetic mutations leading to the activation of several protooncogens and to the 
inactivation of several tumor suppressor genes such as APC (adenomatous polypo-
sis colis), TP53 gene and LOH (loss of heterozygosity), these tumors also demonstra-
te chromosome instability. This is a so-called phenotype or pathway of chromosome 
instability (CIN) and microsatellite stability (MSS) [8,9]. 
A subset of about 15% of CRC display a distinct type of genomic instability, 
referred to as microsatellite instability (MSI) pathway. Instability in two or more 
of several distinct marker loci (MLH1, MSH2, MSH6, PMS2) is defined as MSI-high 
(MSI-H) tumor, whereas those with one unstable marker are designated MSI low 
(MSI-L). Tumors with no positive marker at any of the investigated loci are classi-
fied as microsatellite-stable (MSS). The MSI subtype is caused by a defective DNA 
mismatch repair (MMR) system. The technical determination of the MSI status is 
based either on PCR analysis or immunohistochemistry (IHC). In about one third 
of cases, the MSI-H phenotype results from a germline mutation in one of the MMR 
genes. More commonly, MSI-H is sporadic and due to somatic or epigenetic events, 
for example due to MLH1 gene promoter methylation [8,9,12].
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The epigenetic inactivation of the MLH1 gene in CRC is generally associated 
with an extensive hypermethylation of many other promoter regions, also known as 
the CpG island methylation phenotype or pathway (CIMP). The CIMP subtype in-
cludes a broader spectrum of tumors than the MSI subtype. Technological advances 
allowing for genome-wide DNA methylation profiling have revealed recently, that 
aberrant DNA methylation is not restricted to promoters, but occurs genome-wide, 
including intragenic and intergenic regions. Promoter methylation is often linked to 
the silencing of genes, whereas intragenic methylation is positively correlated with 
gene expression [8,9].
All these subtypes may require different clinical management and treatment 
strategies. For example, in patients with stage II disease mismatch repair deficiency 
(dMMR) is a predictive biomarker for lack of significant benefit from adjuvant sin-
gle-agent fluoropyrimidine chemotherapy in this population [4,6].
Another CRC classification system, based on the cancer genome atlas (TCGA) 
analysis, considers the rate of somatic mutations that can vary considerably among 
tumors. About 16% of tumors were found to be hypermutated (defined as >12 mu-
tations per 106 bases) with somatic events in either DNA mismatch repair genes—
manifesting also as the MSI-H phenotype — or in a related DNA repair gene (such 
as POLE) not entirely. TGFBR2 and BRAF were frequent targets of mutation, too, fo-
und in about 50% of hypermutated, but less than 5% of non-hypermutated tumors. In 
contrast, the group of non-hypermutated tumors is very well associated with CIN+ 
tumors. The most frequently mutated genes among them were APC, TP53, KRAS, 
PIK3CA, FBXW7, and NRAS, indicating that hypermutated and non-hypermutated 
tumors progress through different sequences of genetic events and pathways [8,9,13].
Moreover, recent unsupervised approach using gene modules resulted in the 
identification and/or proposition of five distinct molecularly defined CRC subtypes, 
which adds a new layer of complexity to CRC heterogeneity and opens new oppor-
tunities for understanding the disease [8,14]. 
All this emerging data confirm that CRC, despite similar histology across cases, 
is a heterogeneous group of tumors that can be subdivided by their molecular fea-
tures and treated differently; e.g., microsatellite instable (MSI) versus microsatellite 
stable (MSS), RAS mutated versus wildtype, BRAF mutated versus wildtype, and 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) mutated versus wildtype 
[4,8,9,13,14]. 
A majority of newly diagnosed patients present with stage I – III disease that is 
confined to the bowel and regional lymph nodes, whereas about a third is diagno-
sed with metastatic disease. Early stage CRC might be curable with surgery alone or 
in combination with systemic adjuvant chemotherapy and radiotherapy (for rectal 
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cancer). Radiotherapy can be applied as neoadjuvant or as adjuvant. Neverthele-
ss, a considerable proportion of these patients experience disease recurrence after 
surgical resection (and adjuvant therapy) or develop metastatic disease, indicating 
again that supplemental parameters and biomarkers for risk estimation in clinical 
practice beyond the TNM classification and pathological risk factors are needed. In 
developed countries, there is a trend of improvement in CRC mortality, probably 
due to an earlier diagnosis through screening, more precise diagnostic equipment 
and algorithms, and better treatment modalities [4-7,15].
The backbone of chemotherapy in CRC is 5-fluorouracil (5-FU), a pyrimidine ana-
log that disrupts DNA and RNA synthesis. When 5-FU is administered intravenously, 
it is given with leucovorin, a folate analog that stabilizes thymidylate synthetase and 
enhances the cytotoxicity of 5-FU. Oral capecitabine is a prodrug, that is enzymati-
cally converted to 5-FU in the body and can be used instead of 5-FU. 5-FU is active as a 
single agent, but its efficacy and patients’ survival are improved in a metastatic setting 
when combined with oxaliplatin, a platinum derivative and alkylating agent, or with 
irinotecan, a topoisomerase I inhibitor that affects DNA repair. In selected patients, 
a feasible treatment option may be a combination of all three agents (FOLFOXIRI). 
There is evidence for improved response rate and survival with the latter chemothera-
py protocol, but at the cost of increased toxicity (side-effects), including neurotoxicity 
and neutropenia. Various studies have investigated whether molecular differences 
between patients can predict response to standard chemotherapy drugs to facilitate a 
more personalized approach to chemotherapy. Analyses regarding the genes or their 
products that may be targeted by such cytostatics or may be involved in the metaboli-
sm of these cytostatics or in repairing the damage to (tumor) DNA molecule caused by 
these agents are not in routine use. In a disease metastatic setting, including the abo-
vementioned cytotoxic drugs, both the vascular endothelial growth factor (VEGF)-A-
targeted antibody bevacizumab and the epidermal growth factor receptor (EGFR)-
targeted antibodies cetuximab and panitumumab have clear efficacy when combined 
with particular cytotoxic chemotherapeutic regimens, the latter group in KRAS and 
NRAS-wildtype disease only. For bevacizumab, we have no predictive parameter or 
marker. Another biologic agent that targets the VEGF pathway is aflibercept, a recom-
binant protein with VEGF receptors 1 and 2 that targets VEGF-A, VEGF-B, and placen-
tal growth factor (PlGF). The US Food and Drug Administration (FDA) also approved 
the novel agent regorafenib for chemotherapy-refractory mCRC in 2013. Regorafenib 
is an oral tyrosine kinase inhibitor that has multiple targets, including VEGF recep-
tors 1, 2, and 3 [4-7,16-19].
In conclusion, treatment and outcomes for patients with mCRC have been stea-
dily improving with the introduction of newer polychemotherapy protocols along 
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with the use of inhibitors of the vascular endothelial growth factor (VEGF) and 
the epidermal growth factor receptor (EGFR) pathways. Molecular heterogeneity 
of CRC is believed to be one of the main factors responsible for the considerable 
variability in patients’ response to treatment. Whenever possible, treatment should 
be individualized according to patient’s pharmacogenetic characteristics and the 
finding with respect to the predictive genetic alterations in autologous tumor cells. 
Such individualized approach (personalized cancer medicine) may result in more 
rational, higher-quality and more effective treatment with less adverse reactions 
[4-6, 8, 9, 20].
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Sažetak
Kolorektalni rak – uvodnik
U prikazanom uvodnom radu dan je kratak pregled kliničkih aktualnosti u sporadičnom ko-
lorektalnom raku (KR). KR je u svijetu, zajedno s rakom pluća i rakom dojke, jedan od najčešćih 
tipova raka kako po incidenciji tako i u prevalenciji. Nažalost, među zloćudnim tumorima je 
jedan i od češćih uzroka smrti. Većina KR je sporadična, s dobi kao jednim od najvažnih faktora 
rizika. Dijagnoza kolorektalnog raka bazira se na patohistološkim karakteristikama, ali rezultati 
molekularnih istraživanja ukazuju da se radi o skupini heterogenih tumora, koji se razlikuju u 
patogenezi, molekularnim aberacijama, prognozi i odgovoru na primijenjeno liječenje. KR se ra-
zvija kroz postepenu akumulaciju genskih i epigenetskih promjena, s posljedicom transformacije 
normalni stanica mukoze u invazivni rak. Strategija liječenja raka kolorektuma se prvenstveno 
temelji na smještaju tumora, procjeni uznapredovalosti i proširenosti tumora te općem stanju 
bolesnika. Ipak, sve češće kada je moguće, u obzir se uzimaju geni i/ili molekularni putevi koji 
reguliraju aktivnosti kao npr. rast i diobu stanica, njihovu smrt ili apoptozu, popravak molekula 
DNA, i druge slične stanične aktivnosti. Razmjerno noviji polikemoterapijski protokoli kao i upo-
raba inhibitora vaskularnog endotelijalnog faktora rasta i receptora za epidermalni faktor rasta 
poboljšali su liječenje, a moguće i prognozu bolesnika. Za očekivati je da će se unutar nekoliko 
slijedećih godina liječenje bolesnika s kolorektalnim rakom sve više i više temeljiti na nalazu 
molekularnih subtipova raka i prema validiranim prognostičkim i prediktivnim parametrima, jer 
bi takav pristup trebao osigurati bolju terapijsku učinkovitost i manje nuspojava.
Ključne riječi: kolorektalni rak; biomarkeri; kemoterapija; ciljana terapija; radioterapija; per-
sonalizirana medicina.
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